TRACON Pharmaceuticals Inc (NAS:TCON)
$ 1.26 0.02 (1.63%) Market Cap: 3.38 Mil Enterprise Value: -4.95 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

Q1 2019 TRACON Pharmaceuticals Inc Earnings Call Transcript

May 14, 2019 / 08:30PM GMT
Release Date Price: $136.5 (+1.88%)
Operator

Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals First Quarter 2019 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speaker's prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.

During today's call we'll be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, future expenses and cash runway, and our development plans and strategy.

These statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.

Now, I would like to turn the conference call over to Dr. Charles Theuer, President and CEO of TRACON Pharmaceuticals. Dr. Theuer, you may begin.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot